Current therapeutic interventions in the glycation pathway: Evidence from clinical studies

Diabetes, Obesity and Metabolism

Volumn 15, Issue 8, 2013, Pages 677-689

  Engelen, L ^a   Stehouwer, C D A ^a   Schalkwijk, C G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Advanced glycation endproducts; Cardiovascular disease; Diabetes mellitus; Therapy

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; AMINOGUANIDINE; ATORVASTATIN; BENFOTIAMINE; CERIVASTATIN; EPALRESTAT; INFLIXIMAB; METFORMIN; METHOTREXATE; PENTOSIDINE; PRASTERONE; PYRIDOXAMINE; PYRIDOXINE; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; THIAMINE; THIOCTIC ACID;

CLINICAL TRIAL (TOPIC); DRUG EFFECT; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; GLYCATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INTERVENTION STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; WEIGHT REDUCTION;

EID: 84879792938     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12058     Document Type: Review

References (167)

1. World Health Organization. Diabetes: fact sheet no. 312. Available from URL: http://www.who.int/mediacentre/factsheets/fs312/en. 2011. Accessed February 2012.
2. International Diabetes Federation. IDF Diabetes Atlas: the global burden, 5th edition [online]. Available from URL: http://www.idf.org/diabetesatlas/5e/the-global-burden. 2011. Accessed February 2012.
3. The Emerging Risk Factors Collaboration, Sarwar N, Gao P et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
4. The Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841.
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
7. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
9. Stitt AW. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 2001; 85: 746-753.
10. Monnier VM, Cerami A. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 1981; 211: 491-493.
11. Westwood ME, Thornalley PJ. Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. J Protein Chem 1995; 14: 359-372.
12. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994; 94: 110-117.
13. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 1996; 97: 1422-1428.
14. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344(Pt 1): 109-116.
15. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271: 9982-9986.
16. Negre-Salvayre A, Coatrieux C, Ingueneau C, Salvayre R. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 2008; 153: 6-20.
17. Monnier VM, Stevens VJ, Cerami A. Maillard reactions involving proteins and carbohydrates in vivo: relevance to diabetes mellitus and aging. Prog Food Nutr Sci 1981; 5: 315-327.
18. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67: 3-21.
19. Baynes JW. The role of AGEs in aging: causation or correlation. Exp Gerontol 2001; 36: 1527-1537.
20. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146.
21. Smit AJ, Lutgers HL. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 2004; 11: 2767-2784.
22. Thornalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 2002; 50: 37-57.
23. Tilton RG. Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF. Microsc Res Tech 2002; 57: 390-407.
24. Goh SY, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-1152.
25. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 2007; 9: 233-245.
26. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
27. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003; 21: 3-12.
28. Miyazaki A, Nakayama H, Horiuchi S. Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc Med 2002; 12: 258-262.
29. Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002; 1: 1-15.
30. Shinohara M, Thornalley PJ, Giardino I et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 1998; 101: 1142-1147.
31. Monnier VM. Intervention against the Maillard reaction in vivo. Arch Biochem Biophys 2003; 419: 1-15.
32. Nagai R, Murray DB, Metz TO, Baynes JW. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes 2012; 61: 549-559.
33. Schalkwijk CG. Therapeutic interventions in the glyc(oxid)ation pathway. Immun Endoc & Metab Agents in Med Chem 2007; 7: 57-68.
34. Sourris KC, Harcourt BE, Forbes JM. A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches? Am J Nephrol 2009; 30: 323-335.
35. Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes. Pathol Biol (Paris) 2006; 54: 405-419.
36. Schalkwijk CG, Miyata T. Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics. Amino Acids 2012; 42: 1193-1204.
37. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003; 419: 31-40.
38. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232: 1629-1632.
39. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994; 43: 676-683.
40. Huijberts MS, Wolffenbuttel BH, Boudier HA et al. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993; 92: 1407-1411.
41. Birrell AM, Heffernan SJ, Kirwan P, McLennan S, Gillin AG, Yue DK. The effects of aminoguanidine on renal changes in a baboon model of Type 1 diabetes. J Diabetes Complications 2002; 16: 301-309.
42. Edelstein D, Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 1992; 35: 96-97.
43. Yamauchi A, Takei I, Makita Z et al. Effects of aminoguanidine on serum advanced glycation endproducts, urinary albilmin excretion, mesangial expansion, and glomerular basement membrane thickening in Otsuka Long-Evans Tokushima fatty rats. Diabetes Res Clin Pract 1997; 34: 127-133.
44. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-1334.
45. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 1991; 88: 11555-11558.
46. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001; 50: 1636-1642.
47. Miyauchi Y, Shikama H, Takasu T et al. Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozocin-induced diabetic rats. Eur J Endocrinol 1996; 134: 467-473.
48. Schmidt RE, Dorsey DA, Beaudet LN, Reiser KM, Williamson JR, Tilton RG. Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomic ganglia of rats with streptozocin-induced diabetes. Diabetes 1996; 45: 284-290.
49. Asif M, Egan J, Vasan S et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A 2000; 97: 2809-2813.
50. Candido R, Forbes JM, Thomas MC et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92: 785-792.
51. Vaitkevicius PV, Lane M, Spurgeon H et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A 2001; 98: 1171-1175.
52. Vasan S, Zhang X, Zhang X et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996; 382: 275-278.
53. Wolffenbuttel BH, Boulanger CM, Crijns FR et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998; 95: 4630-4634.
54. Forbes JM, Yee LT, Thallas V et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004; 53: 1813-1823.
55. Forbes JM, Thallas V, Thomas MC et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003; 17: 1762-1764.
56. Lassila M, Seah KK, Allen TJ et al. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 2004; 15: 2125-2138.
57. Thallas-Bonke V, Lindschau C, Rizkalla B et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 2004; 53: 2921-2930.
58. Booth AA, Khalifah RG, Hudson BG. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 1996; 220: 113-119.
59. Booth AA, Khalifah RG, Todd P, Hudson BG. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 1997; 272: 5430-5437.
60. Alkhalaf A, Klooster A, van Oeveren W et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010; 33: 1598-1601.
61. Degenhardt TP, Alderson NL, Arrington DD et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61: 939-950.
62. Hammes HP, Du X, Edelstein D et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-299.
63. Stitt A, Gardiner TA, Alderson NL et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51: 2826-2832.
64. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52: 2110-2120.
65. Balakumar P, Chakkarwar VA, Singh M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell Biochem 2009; 320: 149-162.
66. Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley PJ. Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia 2010; 53: 1506-1516.
67. Bolton WK, Cattran DC, Williams ME et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40.
68. Freedman BI, Wuerth JP, Cartwright K et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999; 20: 493-510.
69. Suji G, Sivakami S. DNA damage by free radical production by aminoguanidine. Ann N Y Acad Sci 2006; 1067: 191-199.
70. Tilton RG, Chang K, Hasan KS et al. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993; 42: 221-232.
71. Turgut F, Bolton WK. Potential new therapeutic agents for diabetic kidney disease. Am J Kidney Dis 2010; 55: 928-940.
72. Kass DA, Shapiro EP, Kawaguchi M et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104: 1464-1470.
73. Hartog JW, Willemsen S, van Veldhuisen DJ et al. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail 2011; 13: 899-908.
74. Zieman SJ, Melenovsky V, Clattenburg L et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 2007; 25: 577-583.
75. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11: 191-195.
76. ClinicalTrials.gov. Registry and results database of federally and privately supported clinical trials conducted in the United States and around the world. Available from URL: http://www.clinicaltrials.gov/ct2/results?term=alagebrium. 2012. Accessed February 2012.
77. Voziyan PA, Khalifah RG, Thibaudeau C et al. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J Biol Chem 2003; 278: 46616-46624.
78. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007; 27: 605-614.
79. Lewis EJ, Greene T, Spitalewiz S et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2012; 23: 131-136.
80. Nascimento MM, Suliman ME, Murayama Y et al. Effect of high-dose thiamine and pyridoxine on advanced glycation end products and other oxidative stress markers in hemodialysis patients: a randomized placebo-controlled study. J Ren Nutr 2006; 16: 119-124.
81. Alkhalaf A, Kleefstra N, Groenier KH et al. Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One 2012; 7: e40427.
82. Schupp N, Dette EM, Schmid U et al. Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients. Naunyn Schmiedebergs Arch Pharmacol 2008; 378: 283-291.
83. Stirban A, Negrean M, Stratmann B et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006; 29: 2064-2071.
84. Du X, Edelstein D, Brownlee M. Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 2008; 51: 1930-1932.
85. Rabbani N, Alam SS, Riaz S et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia 2009; 52: 208-212.
86. Sihag B, Meena B, Agrawal R, Meel J, Sirohi P, Bishnoi P. High dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled study. Diabetes Obes Metab 2010; 12: 87-88.
87. Kawai T, Takei I, Tokui M et al. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(varepsilon)-carboxymethyl lysine. J Diabetes Complications 2010; 24: 424-432.
88. Nakamura N, Yamazaki K, Satoh A et al. Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetes. In Vivo 2003; 17: 177-180.
89. Hamada Y, Nakamura J, Naruse K et al. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care 2000; 23: 1539-1544.
90. Hamada Y, Odagaki Y, Sakakibara F, Naruse K, Koh N, Hotta N. Effects of an aldose reductase inhibitor on erythrocyte fructose 3-phosphate and sorbitol 3-phosphate levels in diabetic patients. Life Sci 1995; 57: 23-29.
91. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 1999; 58: 1765-1773.
92. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
93. Faure P, Wiernsperger N, Polge C, Favier A, Halimi S. Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin. Clin Sci (Lond) 2008; 114: 251-256.
94. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999; 48: 198-202.
95. Rabbani N, Chittari MV, Bodmer CW, Zehnder D, Ceriello A, Thornalley PJ. Increased glycation and oxidative damage to apolipoprotein B100 of LDL cholesterol in patients with type 2 diabetes and effect of metformin. Diabetes 2010; 59: 1038-1045.
96. Diamanti-Kandarakis E, Alexandraki K, Piperi C et al. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism 2007; 56: 129-134.
97. Engelen L, Lund SS, Ferreira I et al. Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes. Eur J Endocrinol 2011; 164: 371-379.
98. Lund SS, Tarnow L, Stehouwer CD et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008; 158: 631-641.
99. Kanazawa I, Yamamoto M, Yamaguchi T, Sugimoto T. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011; 119: 362-365.
100. Yu Y, Thorpe SR, Jenkins AJ et al. Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes. Diabetologia 2006; 49: 2488-2498.
101. Monnier VM, Bautista O, Kenny D et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 1999; 48: 870-880.
102. Norlinah MI, Hamizah R, Md Isa SH, Wan Nazaimoon WM, Khalid BA. The effects of short-term, rapid glycemic control on the peroneal nerve function and serum VCAM-1 and AGE in type 2 diabetic patients in Malaysia. Indian J Med Sci 2009; 63: 131-138.
103. Jaleel A, Halvatsiotis P, Williamson B, Juhasz P, Martin S, Nair KS. Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. Diabetes Care 2005; 28: 645-652.
104. Salmela PI, Oikarinen AI, Ukkola O et al. Improved metabolic control in patients with non-insulin-dependent diabetes mellitus is associated with a slower accumulation of glycation products in collagen. Eur J Clin Invest 1995; 25: 494-500.
105. Schiel R, Franke S, Appel T et al. Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN). Eur J Med Res 2004; 9: 391-399.
106. Schiel R, Franke S, Appel T et al. Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10years (JEVIN). J Diabetes Complications 2003; 17: 90-97.
107. Chiarelli F, de Martino M, Mezzetti A et al. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr 1999; 134: 486-491.
108. Lyons TJ, Bailie KE, Dyer DG, Dunn JA, Baynes JW. Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest 1991; 87: 1910-1915.
109. Mentink CJ, Kilhovd BK, Rondas-Colbers GJ, Torjesen PA, Wolffenbuttel BH. Time course of specific AGEs during optimised glycaemic control in type 2 diabetes. Neth J Med 2006; 64: 10-16.
110. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
111. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
112. Miyata T, van Ypersele de Strihou C, Ueda Y et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-2487.
113. Forbes JM, Thomas MC, Thorpe SR, Alderson NL, Cooper ME. The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int Suppl 2004: S105-S107.
114. Nangaku M, Miyata T, Sada T et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14: 1212-1222.
115. Fan Q, Liao J, Kobayashi M et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19: 3012-3020.
116. Izuhara Y, Sada T, Yanagisawa H et al. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterioscler Thromb Vasc Biol 2008; 28: 1767-1773.
117. Sugiyama T, Okuno T, Fukuhara M et al. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes. Exp Eye Res 2007; 85: 406-412.
118. Thomas MC, Tikellis C, Burns WM et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005; 16: 2976-2984.
119. Forbes JM, Cooper ME, Thallas V et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51: 3274-3282.
120. Liu XP, Pang YJ, Zhu WW et al. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways. Clin Exp Pharmacol Physiol 2009; 36: 287-296.
121. Miyata T, van Ypersele de Strihou C. Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch Biochem Biophys 2003; 419: 50-54.
122. Komiya N, Hirose H, Saisho Y, Saito I, Itoh H. Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension. Int Heart J 2008; 49: 681-689.
123. Mitsuhashi H, Tamura K, Yamauchi J et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis 2009; 207: 186-190.
124. Rabbani N, Adaikalakoteswari A, Rossing K et al. Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. Amino Acids 2012; 42: 1627-1639.
125. Monacelli F, Poggi A, Storace D et al. Effects of valsartan therapy on protein glycoxidation. Metabolism 2006; 55: 1619-1624.
126. Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Diabetes Res Clin Pract 2006; 74: 201-203.
127. Saha SA, LaSalle BK, Clifton GD, Short RA, Tuttle KR. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease-a dose-response relationship study. Am J Ther 2010; 17: 553-558.
128. Persson F, Rossing P, Hovind P et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes 2006; 55: 3550-3555.
129. Engelen L, Persson F, Ferreira I et al. Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial. Nephrol Dial Transplant 2011; 26: 3573-3577.
130. Busch M, Franke S, Wolf G, Rohde RD, Stein G. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract 2008; 108: c291-c297.
131. Sebekova K, Gazdikova K, Syrova D et al. Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products. J Hum Hypertens 2003; 17: 265-270.
132. Nakamura T, Sato E, Fujiwara N et al. Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease. Clin Cardiol 2011; 34: 372-377.
133. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138: 271-280.
134. Akira K, Amano M, Okajima F, Hashimoto T, Oikawa S. Inhibitory effects of amlodipine and fluvastatin on the deposition of advanced glycation end products in aortic wall of cholesterol and fructose-fed rabbits. Biol Pharm Bull 2006; 29: 75-81.
135. Sezer ED, Sozmen EY, Nart D, Onat T. Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation. Vasc Health Risk Manag 2011; 7: 333-343.
136. Jinnouchi Y, Yamagishi S, Takeuchi M et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006; 6: 191-193.
137. Kimura Y, Hyogo H, Yamagishi S et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010; 45: 750-757.
138. Cuccurullo C, Iezzi A, Fazia ML et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006; 26: 2716-2723.
139. Scharnagl H, Stojakovic T, Winkler K, Rosinger S, Marz W, Boehm BO. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2007; 115: 372-375.
140. Tam HL, Shiu SW, Wong Y, Chow WS, Betteridge DJ, Tan KC. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010; 209: 173-177.
141. Kageyama Y, Takahashi M, Ichikawa T, Torikai E, Nagano A. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 73-80.
142. Kageyama Y, Takahashi M, Nagafusa T, Torikai E, Nagano A. Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol Int 2008; 28: 245-251.
143. Kageyama Y, Takahashi M, Nagafusa T, Torikai E, Nagano A. Methotrexate reduces the levels of pentosidine and 8-hydroxy-deoxy guanosine in patients with rheumatoid arthritis. Mod Rheumatol 2007; 17: 398-402.
144. Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 66: 103-109.
145. Gugliucci A, Kotani K, Taing J et al. Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. Ann Nutr Metab 2009; 54: 197-201.
146. Iwashige K, Kouda K, Kouda M et al. Calorie restricted diet and urinary pentosidine in patients with rheumatoid arthritis. J Physiol Anthropol Appl Human Sci 2004; 23: 19-24.
147. Yoshikawa T, Miyazaki A, Fujimoto S. Decrease in serum levels of advanced glycation end-products by short-term lifestyle modification in non-diabetic middle-aged females. Med Sci Monit 2009; 15: PH65-PH73.
148. Diamanti-Kandarakis E, Piperi C, Alexandraki K et al. Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metabolism 2006; 55: 494-500.
149. Diamanti-Kandarakis E, Piperi C, Alexandraki KI et al. The acute effect of Orlistat on dietary glycotoxins in diabetics and healthy women. Minerva Endocrinol 2009; 34: 97-104.
150. Cai W, He JC, Zhu L et al. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004; 110: 285-291.
151. Uribarri J, Cai W, Ramdas M et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011; 34: 1610-1616.
152. Uribarri J, Peppa M, Cai W et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003; 14: 728-731.
153. Vlassara H, Cai W, Goodman S et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 2009; 94: 4483-4491.
154. Jackson S, James M, Abrams P. The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence. BJOG 2002; 109: 339-344.
155. Sundaram RC, Selvaraj N, Vijayan G, Bobby Z, Hamide A, Rattina Dasse N. Increased plasma malondialdehyde and fructosamine in iron deficiency anemia: effect of treatment. Biomed Pharmacother 2007; 61: 682-685.
156. Vijayan G, Sundaram RC, Bobby Z, Hamide A, Selvaraj N, Dasse NR. Increased plasma malondialdehyde and fructosamine in anemic H pylori infected patients: effect of treatment. World J Gastroenterol 2007; 13: 796-800.
157. Brignardello E, Runzo C, Aragno M et al. Dehydroepiandrosterone administration counteracts oxidative imbalance and advanced glycation end product formation in type 2 diabetic patients. Diabetes Care 2007; 30: 2922-2927.
158. Contreras I, Reiser KM, Martinez N et al. Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM. Diabetes Care 1997; 20: 832-835.
159. You WH, Wang P, Li MQ, Zhang Y, Peng YL, Zhang FL. Therapeutic effects of modified Danggui Sini Decoction on plasma level of advanced glycation end products in patients with Wagner grade 0 diabetic foot: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao 2009; 7: 622-628.
160. Kakuta T, Tanaka R, Hyodo T et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011; 57: 422-431.
161. Gomez-Perez FJ, Valles-Sanchez VE, Lopez-Alvarenga JC et al. Vitamin E modifies neither fructosamine nor HbA1c levels in poorly controlled diabetes. Rev Invest Clin 1996; 48: 421-424.
162. Lu L, Erhard P, Salomon RG, Weiss MF. Serum vitamin E and oxidative protein modification in hemodialysis: a randomized clinical trial. Am J Kidney Dis 2007; 50: 305-313.
163. Reaven PD, Herold DA, Barnett J, Edelman S. Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM. Diabetes Care 1995; 18: 807-816.
164. Morano S, Mandosi E, Fallarino M et al. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur Urol 2007; 52: 1768-1774.
165. Scheijen JL, van de Waarenburg MP, Stehouwer CD, Schalkwijk CG. Measurement of pentosidine in human plasma protein by a single-column high-performance liquid chromatography method with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 610-614.
166. Teerlink T, Barto R, Ten Brink HJ, Schalkwijk CG. Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin Chem 2004; 50: 1222-1228.
167. Thornalley PJ, Battah S, Ahmed N et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003; 375: 581-592.